(E)-N-(2-amino-4-fluorophenyl)-4-(cinnamamidomethyl)benzamide | 1347502-26-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N-(2-amino-4-fluorophenyl)-4-(cinnamamidomethyl)benzamide
• 英文别名: N-(2-amino-4-fluorophenyl)-4-[[[(E)-3-phenylprop-2-enoyl]amino]methyl]benzamide
• CAS: 1347502-26-4
• 化学式: C₂₃H₂₀FN₃O₂
• 分子量: 389.429
• InChiKey: ROCSVJSPJGRGIX-MDWZMJQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氨甲基苯甲酸 在 硫酸 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 (E)-N-(2-amino-4-fluorophenyl)-4-(cinnamamidomethyl)benzamide
  参考文献：
  名称：

  烟酰胺磷酸核糖基转移酶（NAMPT）是抗肿瘤药物Chidamide的新目标。

  摘要：

  Chidamide是一种组蛋白脱乙酰基酶（HDAC）抑制剂，目前在临床上用于治疗皮肤T细胞淋巴瘤。在此，基于药效团分析，分子对接，生物学分析，抑制剂设计和结构-活性关系研究，烟酰胺磷酸核糖基转移酶（NAMPT）被确定为几丁质的新靶标。Chidamide的多药理学将为更好地了解其抗肿瘤机制提供重要信息。而且，双重NAMPT / HDAC抑制剂的设计可以作为开发新型抗肿瘤剂的有效策略。

  DOI：

  10.1021/acsmedchemlett.9b00407

文献信息

• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE-DÉSACÉTYLASES
  申请人：BROAD INST INC

  公开号：WO2014018979A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

  本发明涉及式(I)的化合物或其药学上可接受的盐、水合物、溶剂合物或前药，其中X1、X2、X3、X4、X5、W1、W2、W3和W4如所述。本发明一般涉及组织脱乙酰化酶抑制剂以及制备和使用它们的方法。在一个方面，该发明涉及选择性HDAC3抑制剂，可用于保护β细胞并改善胰岛素抵抗。选择性HDAC3抑制剂还可用于促进认知功能，增强学习和记忆形成。本发明的化合物可用于治疗、缓解和/或预防各种疾病，例如代谢紊乱，如1型或2型糖尿病、血脂异常、脂肪萎缩、与代谢综合征相关的肝病、多囊卵巢综合征或肥胖症；炎症性疾病；神经系统疾病；记忆或认知功能障碍；消除学习障碍；真菌疾病或感染；病毒性疾病或感染，如艾滋病病毒；血液病；肝病；溶酶体贮积病；或人类或动物的肿瘤性疾病。
• Histone Deacetylase Inhibitors or Novel Benzamine Derivatives with Potent Differentiation and Anti-Proliferation Activity
  申请人：Lu Xian-Ping

  公开号：US20080039509A1

  公开（公告）日：2008-02-14

  The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis.

  本发明涉及一种新的苯甲酰胺衍生物的制备和药物应用，该衍生物的定义如公式(I)所述，作为组蛋白去乙酰化酶抑制剂（HDACI），其制备方法以及使用这些化合物或其药学上可接受的盐治疗细胞增殖性疾病，例如癌症和牛皮癣。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：The General Hospital Corporation d/b/a Massachusetts General Hospital

  公开号：US20150191427A1

  公开（公告）日：2015-07-09

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , W 1 , W 2 , W 3 , and W 4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

  本发明涉及公式(I)的化合物或其药学上可接受的盐、水合物、溶剂物或前药，其中X1、X2、X3、X4、X5、W1、W2、W3和W4如所述。本发明通常涉及组织脱乙酰化酶抑制剂及其制备和使用方法。在一个方面，本发明涉及选择性HDAC3抑制剂，用于保护β细胞和改善胰岛素抵抗力。选择性HDAC3抑制剂还有助于促进认知功能和增强学习和记忆形成。本发明的化合物可用于治疗、缓解和/或预防各种疾病，包括代谢紊乱，例如1型或2型糖尿病、脂质代谢异常、脂肪萎缩症、代谢综合征相关的肝病、多囊卵巢综合征或肥胖症；炎症性疾病；神经系统疾病；记忆或认知功能障碍；灭绝学习障碍；真菌疾病或感染；病毒性疾病或感染，如HIV；血液学疾病；肝脏疾病；溶酶体贮积病；或动物中的肿瘤性疾病。
• Inhibitors of histone deacetylase
  申请人：The Broad Institute, Inc.

  公开号：US11377423B2

  公开（公告）日：2022-07-05

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

  本发明涉及式（I）化合物： 或其药学上可接受的盐、水合物、溶液或原药，其中 X1、X2、X3、X4、X5、W1、W2、W3 和 W4 如本文所述。本发明一般涉及组蛋白去乙酰化酶抑制剂及其制造和使用方法。一方面，本发明涉及用于保护β细胞和改善胰岛素抵抗的选择性HDAC3抑制剂。选择性 HDAC3 抑制剂还有助于促进认知功能，增强学习和记忆的形成。本发明的化合物可用于治疗、缓解和/或预防各种疾病，例如包括代谢紊乱，如 1 型或 2 型糖尿病、血脂异常、脂肪变性、与代谢综合征相关的肝病、多囊卵巢综合征或肥胖症；炎症性疾病；神经系统疾病；记忆或认知功能障碍/受损；绝迹学习障碍；真菌疾病或感染；病毒性疾病或感染，如艾滋病毒；血液病；肝病；溶酶体贮存疾病；或人类或动物的肿瘤性疾病。
• US7244751B2
  申请人：——

  公开号：US7244751B2

  公开（公告）日：2007-07-17